ACRS - Aclaris Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.4300
+0.0300 (+0.68%)
As of 11:28AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.4000
Open4.4500
Bid4.4000 x 1300
Ask4.4200 x 800
Day's Range4.3200 - 4.4700
52 Week Range4.2690 - 21.9690
Volume46,940
Avg. Volume497,029
Market Cap184.914M
Beta (3Y Monthly)1.60
PE Ratio (TTM)N/A
EPS (TTM)-3.9460
Earnings DateMar 14, 2019 - Mar 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.83
Trade prices are not sourced from all markets
  • FDA asks Chester County biopharm company to pull promotional video
    American City Business Journals48 minutes ago

    FDA asks Chester County biopharm company to pull promotional video

    The federal agenecy claims the video has misleading and incomplete information about the company's skin disorder treatment.

  • GlobeNewswire22 hours ago

    ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. (“Aclaris” or “the Company”) (NASDAQ: ACRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. It was reported on June 20, 2019, that the FDA’s Office of Prescription Drug Promotion (OPDP) released a letter which stated that a video advertisement for Aclaris’s hydrogen peroxide topical solution, Eskata, “makes false or misleading claims” about its risk and efficacy. The FDA letter states that, “a direct-to-consumer video of an interview featuring a paid Aclaris spokesperson” was “especially concerning from a public health perspective because it fails to include information regarding the serious risks associated with Eskata, which bears warnings and precautions related to the risks of serious eye disorders .

  • Business Wire2 days ago

    Glancy Prongay & Murray LLP Announces Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS)

    Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS) investors concerning the Company and its officers’ possible violations of federal securities laws. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. On June 20, 2019, the U.S. Food & Drug Administration (“FDA”) stated that an advertisement for Aclaris’s hydrogen peroxide topical solution, Eskata, “makes false or misleading claims” regarding the product’s risk and efficacy.

  • Business Wire2 days ago

    INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. (“Aclaris” or “the Company”) (NASDAQ: ACRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. It was reported on June 20, 2019, that the FDA’s Office of Prescription Drug Promotion (OPDP) released a letter which stated that a video advertisement for Aclaris’s hydrogen peroxide topical solution, Eskata, “makes false or misleading claims” about its risk and efficacy.

  • Business Wire2 days ago

    INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Aclaris Therapeutics, Inc. Investors (ACRS)

    Law Offices of Howard G. Smith announces an investigation on behalf of Aclaris Therapeutics, Inc. investors concerning the Company and its officers’ possible violations of federal securities laws.

  • ACCESSWIRE2 days ago

    Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aclaris Therapeutics, Inc. (ACRS)

    NEW YORK, NY / ACCESSWIRE / June 24, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aclaris Therapeutics, Inc. ("Aclaris" or the "Company") ...

  • Business Wire4 days ago

    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aclaris Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. (“Aclaris” or “the Company”) (NASDAQ: ACRS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. It was reported on June 20, 2019, that the FDA’s Office of Prescription Drug Promotion (OPDP) released a letter which stated that a video advertisement for Aclaris’s hydrogen peroxide topical solution, Eskata, “makes false or misleading claims” about its risk and efficacy.

  • Business Wire5 days ago

    ROSEN, A TOP RANKED LAW FIRM, Announces Investigation of Securities Claims Against Aclaris Therapeutics, Inc. - ACRS

    Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Aclaris Therapeutics, Inc. resulting from allegations that Aclaris may have issued materially misleading business information to the investing public.

  • GlobeNewswire5 days ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aclaris Therapeutics, Inc. - ACRS

    Pomerantz LLP is investigating claims on behalf of investors of Aclaris Therapeutics, Inc. (“Aclaris” or the “Company”) (NASDAQ: ACRS).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. On June 20, 2019, the U.S. Food & Drug Administration (“FDA”) asserted that an Aclaris advertisement for its Eskata hydrogen peroxide topical solution “makes false or misleading claims” regarding the product’s risk and efficacy.  Specifically, the FDA stated that “a direct-to-consumer video of an interview featuring a paid Aclaris spokesperson” was “especially concerning from a public health perspective because it fails to include information regarding the serious risks associated with Eskata, which bears warnings and precautions related to the risks of serious eye disorders .

  • Help may be on the way, via this Malvern biopharm firm, for male/female pattern baldness
    American City Business Journals9 days ago

    Help may be on the way, via this Malvern biopharm firm, for male/female pattern baldness

    The Chester County company posted positive results from a mid-stage clinical trial of its new drug candidate for a condition that affects an estimated 80 million adults in the United States.

  • Benzinga9 days ago

    Aclaris Announces Positive Results From Alopecia Treatment Trial

    Aclaris Therapeutics, Inc. (NASDAQ: ACRS ) announced positive six-month results from a Phase 2 clinical trial of ATI-502 for patients with androgenetic alopecia. The trial evaluated ATI-502 in women and ...

  • GlobeNewswire9 days ago

    Aclaris Therapeutics Announces Positive 6-Month Results from a Phase 2 Open-Label Clinical Trial of ATI-502 Topical in Patients with Androgenetic Alopecia (Male/Female Pattern-Baldness)

    Aclaris Therapeutics, Inc. (ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced positive results from a Phase 2 open-label clinical trial of ATI-502 (AGA-201), an investigational topical Janus Kinase (JAK) 1/3 inhibitor, in patients with androgenetic alopecia (AGA), a condition commonly known as male/female-pattern baldness. The primary endpoint was the mean change from baseline in non-vellus target area hair count (TAHC) at week 26.  The overall change was an increase of 8.6 hairs/cm2. TAHC increase was 15.3 hairs/cm2 in female subjects and 5.6 hairs/cm2 in male subjects.

  • GlobeNewswire12 days ago

    Aclaris Therapeutics to Present at the 2019 JMP Securities Life Sciences Conference

    WAYNE, Pa., June 14, 2019 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases,.

  • Thomson Reuters StreetEvents18 days ago

    Edited Transcript of ACRS earnings conference call or presentation 8-May-19 9:00pm GMT

    Q1 2019 Aclaris Therapeutics Inc Earnings Call

  • GlobeNewswirelast month

    Aclaris Therapeutics to Present at Jefferies 2019 Global Healthcare Conference

    WAYNE, Pa., May 24, 2019 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases,.

  • Rigel Initiates Enrollment in Pivotal Blood Disorder Study
    Zackslast month

    Rigel Initiates Enrollment in Pivotal Blood Disorder Study

    Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.

  • Aclaris Therapeutics, Inc. (ACRS) Q1 2019 Earnings Call Transcript
    Motley Foollast month

    Aclaris Therapeutics, Inc. (ACRS) Q1 2019 Earnings Call Transcript

    ACRS earnings call for the period ending March 31, 2019.

  • Aclaris Therapeutics (ACRS) Reports Q1 Loss, Lags Revenue Estimates
    Zacks2 months ago

    Aclaris Therapeutics (ACRS) Reports Q1 Loss, Lags Revenue Estimates

    Aclaris (ACRS) delivered earnings and revenue surprises of -13.75% and -1.74%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Aclaris: 1Q Earnings Snapshot

    The Wayne, Pennsylvania-based company said it had a loss of 91 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire2 months ago

    Aclaris Therapeutics Reports First Quarter 2019 Financial Results and Provides Update on Clinical and Commercial Developments

    It would be Aclaris’ first internally-developed novel compound to enter the clinical phase of development and its first inflammatory indication adjacent to dermatology. Aclaris expects to begin a Phase 1 clinical trial of ATI-450, an investigational compound, in the second half of 2019. In April 2019, Aclaris completed enrollment of more than 1,000 patients across two Phase 3 pivotal clinical trials (THWART-1 and THWART-2) investigating A-101 45% Topical Solution, an investigational drug, for the treatment of common warts, and expects to complete enrollment of Aclaris’ open-label safety extension trial (WART-303) evaluating the long-term safety of A-101 45% Topical Solution during the second quarter of 2019.

  • How Do Analysts See Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Performing In The Years Ahead?
    Simply Wall St.2 months ago

    How Do Analysts See Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Performing In The Years Ahead?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The most recent earnings release Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) announced in December 201...

  • GlobeNewswire2 months ago

    Aclaris Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019

    WAYNE, Pa., May 01, 2019 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases,.

  • GlobeNewswire2 months ago

    Aclaris Therapeutics Submits Investigational New Drug Application for ATI-450, an oral MK2 inhibitor, for the Treatment of Rheumatoid Arthritis

    Aclaris Therapeutics, Inc. (ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced that it has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for ATI-450, an oral MK2 inhibitor, for the treatment of rheumatoid arthritis (RA).

  • GlobeNewswire2 months ago

    Aclaris Therapeutics Announces Issuance of a Patent Covering the use of Ruxolitinib and its Deuterated Forms to Treat Alopecia Areata

    Aclaris Therapeutics, Inc. (ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 10,265,258 covering methods of treating alopecia areata (AA) using ruxolitinib or isotopic forms of ruxolitinib. This newly issued patent is the latest in a series of patents granted by the USPTO which are exclusively licensed to Aclaris by The Trustees of Columbia University in the City of New York in connection with Aclaris’ janus kinase (JAK) inhibitor program for hair loss disorders. This IP arose out of the novel breakthrough research conducted by Dr. Angela Christiano and her team at Columbia University.

  • Consider These 3 Falling Knives
    GuruFocus.com3 months ago

    Consider These 3 Falling Knives

    Wall Street issued a buy recommendation rating for all three stocks, increasing the likelihood of them outperforming the S&P 500 Index over the next 52 weeks. Warning! GuruFocus has detected 2 Warning Sign with CTMX. Further, these companies have a GuruFocus financial strength rating of at least 5 out of 10, reducing the bankruptcy rate risk, which is quite common among falling knives.